Article
New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
Biochemical pharmacology - 15 Nov 2010
Lagler Florian B, Gersting Søren W, Zsifkovits Clemens, Steinbacher Alice, Eichinger Anna, Danecka Marta K, Staudigl Michael, Fingerhut Ralph, Glossmann Hartmut, Muntau Ania C
Abstract excerpt
Phenylketonuria (PKU), an autosomal recessive disease with phenylalanine hydroxylase (PAH) deficiency, was recently shown to be a protein misfolding disease with loss-of-function. It can be treated by oral application of the natural PAH cofactor tetrahydrobiopterin (BH(4)) that acts as a pharmacological chaperone and rescues enzyme function in vivo. Here we identified Pah(enu1/2) bearing a mild and a severe...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
